Literature DB >> 29309770

A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study.

E Dakwar1, E V Nunes2, C L Hart3, M C Hu4, R W Foltin2, F R Levin2.   

Abstract

Efforts to translate sub-anesthetic ketamine infusions into widespread clinical use have centered around developing medications with comparable neurobiological activity, but with attenuated psychoactive effects so as to minimize the risk of behavioral toxicity and abuse liability. Converging lines of research, however, suggest that some of the psychoactive effects of sub-anesthetic ketamine may have therapeutic potential. Here, we assess whether a subset of these effects - the so-called mystical-type experience - mediates the effect of ketamine on craving and cocaine use in cocaine dependent research volunteers. We found that ketamine leads to significantly greater acute mystical-type effects (by Hood Mysticism Scale: HMS), dissociation (by Clinician Administered Dissociative States Scale: CADSS), and near-death experience phenomena (by the Near-Death Experience Scale: NDES), relative to the active control midazolam. HMS score, but not the CADSS or NDES score, was found to mediate the effect of ketamine on global improvement (decreased cocaine use and craving) over the post-infusion period. This is the first controlled study to show that mystical-type phenomena, long considered to have therapeutic potential, may work to impact decision-making and behavior in a sustained manner. These data suggest that an important direction for medication development is the identification of ketamine-like pharmacotherapy that is selectively psychoactive (as opposed to free of experiential effects entirely), so that mystical-type perspectival shifts are more reliably produced and factors lending to abuse or behavioral impairment are minimized. Future research can further clarify the relationship between medication-occasioned mystical-type effects and clinical benefit for different disorders. This article is part of the Special Issue entitled 'Psychedelics: New Doors, Altered Perceptions'.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Addiction; Cocaine; Hallucinogen; Ketamine; Mystical experience; Psychedelic; Psychoactive effects

Mesh:

Substances:

Year:  2018        PMID: 29309770      PMCID: PMC6033686          DOI: 10.1016/j.neuropharm.2018.01.005

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  34 in total

Review 1.  The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.

Authors:  Franz X Vollenweider; Michael Kometer
Journal:  Nat Rev Neurosci       Date:  2010-08-18       Impact factor: 34.870

2.  Near-death experiences, posttraumatic growth, and life satisfaction among burn survivors.

Authors:  David Royse; Karen Badger
Journal:  Soc Work Health Care       Date:  2017-01-09

Review 3.  Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?

Authors:  Gerard Sanacora; Alan F Schatzberg
Journal:  Neuropsychopharmacology       Date:  2014-09-26       Impact factor: 7.853

4.  Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.

Authors:  Michael P Bogenschutz; Alyssa A Forcehimes; Jessica A Pommy; Claire E Wilcox; P C R Barbosa; Rick J Strassman
Journal:  J Psychopharmacol       Date:  2015-01-13       Impact factor: 4.153

5.  The near-death experience scale. Construction, reliability, and validity.

Authors:  B Greyson
Journal:  J Nerv Ment Dis       Date:  1983-06       Impact factor: 2.254

6.  Functional Segregation of the Human Dorsomedial Prefrontal Cortex.

Authors:  Simon B Eickhoff; Angela R Laird; Peter T Fox; Danilo Bzdok; Lukas Hensel
Journal:  Cereb Cortex       Date:  2014-10-20       Impact factor: 5.357

Review 7.  Reviewing the ketamine model for schizophrenia.

Authors:  Joel Frohlich; John D Van Horn
Journal:  J Psychopharmacol       Date:  2013-11-20       Impact factor: 4.153

8.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

9.  The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers.

Authors:  Elias Dakwar; Frances Levin; Richard W Foltin; Edward V Nunes; Carl L Hart
Journal:  Biol Psychiatry       Date:  2013-09-12       Impact factor: 13.382

10.  Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial.

Authors:  E Dakwar; C L Hart; F R Levin; E V Nunes; R W Foltin
Journal:  Mol Psychiatry       Date:  2016-04-19       Impact factor: 15.992

View more
  14 in total

Review 1.  Semiology and Mechanisms of Near-Death Experiences.

Authors:  Costanza Peinkhofer; Jens P Dreier; Daniel Kondziella
Journal:  Curr Neurol Neurosci Rep       Date:  2019-07-27       Impact factor: 5.081

Review 2.  Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.

Authors:  Nina Schimmel; Joost J Breeksema; Sanne Y Smith-Apeldoorn; Jolien Veraart; Wim van den Brink; Robert A Schoevers
Journal:  Psychopharmacology (Berl)       Date:  2021-11-23       Impact factor: 4.530

Review 3.  Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature.

Authors:  Sandra J Drozdz; Akash Goel; Matthew W McGarr; Joel Katz; Paul Ritvo; Gabriella F Mattina; Venkat Bhat; Calvin Diep; Karim S Ladha
Journal:  J Pain Res       Date:  2022-06-15       Impact factor: 2.832

4.  Effects of psilocybin therapy on personality structure.

Authors:  D Erritzoe; L Roseman; M M Nour; K MacLean; M Kaelen; D J Nutt; R L Carhart-Harris
Journal:  Acta Psychiatr Scand       Date:  2018-06-19       Impact factor: 6.392

5.  Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature.

Authors:  Giovanni Martinotti; Stefania Chiappini; Mauro Pettorruso; Alessio Mosca; Andrea Miuli; Francesco Di Carlo; Giacomo D'Andrea; Roberta Collevecchio; Ilenia Di Muzio; Stefano L Sensi; Massimo Di Giannantonio
Journal:  Brain Sci       Date:  2021-06-27

6.  "This Is Something That Changed My Life": A Qualitative Study of Patients' Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders.

Authors:  O Merve Mollaahmetoglu; Johanna Keeler; Katherine J Ashbullby; Eirini Ketzitzidou-Argyri; Meryem Grabski; Celia J A Morgan
Journal:  Front Psychiatry       Date:  2021-08-16       Impact factor: 4.157

7.  Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing.

Authors:  Jennifer Swainson; Larry J Klassen; Stefan Brennan; Pratap Chokka; Martin A Katzman; Robert L Tanguay; Atul Khullar
Journal:  CNS Drugs       Date:  2022-02-14       Impact factor: 5.749

Review 8.  Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review.

Authors:  Jennifer L Jones; Camilo F Mateus; Robert J Malcolm; Kathleen T Brady; Sudie E Back
Journal:  Front Psychiatry       Date:  2018-07-24       Impact factor: 4.157

Review 9.  Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies.

Authors:  Joost J Breeksema; Alistair R Niemeijer; Erwin Krediet; Eric Vermetten; Robert A Schoevers
Journal:  CNS Drugs       Date:  2020-09       Impact factor: 5.749

Review 10.  Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review.

Authors:  Zach Walsh; Ozden Merve Mollaahmetoglu; Joseph Rootman; Shannon Golsof; Johanna Keeler; Beth Marsh; David J Nutt; Celia J A Morgan
Journal:  BJPsych Open       Date:  2021-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.